nach oben

Erschienen in:

20.02.2021 | Original Communication

CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma

verfasst von: Aurelian Ungureanu, Magali Le Garff-Tavernier, Myrto Costopoulos, Timothée Parratte, Abdelmalek Brinet, Hélène Durand, Claude Gaultier, Remy Hurstel, Isabelle Alamome, François Sellal, Guido Ahle

Erschienen in: Journal of Neurology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Interleukin 6 (IL-6) is a pleomorphic cytokine that can be found in the cerebrospinal fluid (CSF) in a wide spectrum of inflammatory pathologies of the central nervous system (CNS).

Objective

Our aim was to characterize the diagnostic significance of CSF IL-6 among various CNS inflammatory diseases with pseudotumoral lesions (CNSID) and primary CNS lymphoma (PCNSL).

Methods

We retrospectively analyzed the CSF IL-6 concentrations in 43 consecutive patients with suspected PCNSL. A total of 28 patients were positively diagnosed with PCNSL and 15 with CNSID. We verified the results with CSF IL-10, an established biomarker for PCNSL.

Results

In the PCNSL group, the median CSF IL-6 concentration was 8 pg/ml, interquartile range (IQR) 5–18.5. For the patients with CNSID, the median concentration was 70 pg/ml, IQR 5–1368. A group comparison showed significantly higher CSF IL-6 levels in patients with CNSID than in those with PCNSL (p = 0.032). Moreover, IL-6 was correlated with CSF cell count in the CNSID group (r = 0.56, p = 0.028), but not in the PCNSL group (r = 0.3, p = 0.13).

We found significantly higher CSF IL-10 levels in patients with PCNSL than in patients with CNS inflammatory lesions (p < 0.001).

Discussion and conclusions

Our study suggests that CSF IL-6 levels could represent, in addition to CSF IL-10, a useful biomarker in the differential diagnosis of CNSID and suspected PCNSL.

Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https://doi.org/10.1101/cshperspect.a016295CrossRefPubMedPubMedCentral

Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238. https://doi.org/10.1038/nature04753CrossRefPubMed

Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517. https://doi.org/10.1146/annurev.immunol.021908.132710CrossRefPubMed

Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T (1988) IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. Journal of Immunology 141(5):1543–1549

Sasagawa Y, Akai T, Tachibana O, Iizuka H (2015) Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system. J Neurooncol 121(1):177–183. https://doi.org/10.1007/s11060-014-1622-zCrossRefPubMed

Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Investig 93(1):424–428. https://doi.org/10.1172/JCI116977CrossRefPubMedPubMedCentral

Sasayama T, Nakamizo S, Nishihara M, Kawamura A, Tanaka H, Mizukawa K, Miyake S, Taniguchi M, Hosoda K, Kohmura E (2012) Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-oncology 14(3):368–380. https://doi.org/10.1093/neuonc/nor203CrossRefPubMed

Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Beral H, Le Garff-Tavernier M, Soussain C, French LOC Network for CNS Lymphoma (2016) The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer 61:69–76. https://doi.org/10.1016/j.ejca.2016.03.080CrossRefPubMed

Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121(23):4740–4748. https://doi.org/10.1182/blood-2013-01-476333CrossRefPubMedPubMedCentral

10.

van Westrhenen A, Smidt LCA, Seute T, Nierkens S, Stork ACJ, Minnema MC, Snijders TJ (2018) Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review. Br J Haematol 182(3):384–403. https://doi.org/10.1111/bjh.15410CrossRefPubMedPubMedCentral

11.

Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M (2016) How to facilitate early diagnosis of CNS involvement in malignant lymphoma. Expert Rev Hematol 9(11):1081–1091. https://doi.org/10.1080/17474086.2016.1242405CrossRefPubMed

12.

Ikeguchi R, Shimizu Y, Shimizu S, Kitagawa K (2018) CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. Multiple Sclerosis 24(9):1212–1223. https://doi.org/10.1177/1352458517717804CrossRefPubMed

13.

Barrantes-Freer A, Engel AS, Rodriguez-Villagra OA, Winkler A, Bergmann M, Mawrin C, Kuempfel T, Pellkofer H, Metz I, Bleckmann A, Hernandez-Duran S, Schippling S, Rushing EJ, Frank S, Glatzel M, Matschke J, Hartmann C, Reifenberger G, Muller W, Schildhaus HU, Bruck W, Stadelmann C (2018) Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination. Brain Pathol 28(2):225–233. https://doi.org/10.1111/bpa.12496CrossRefPubMed

14.

Houillier C, Soussain C, Ghesquieres H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agape P, Molucon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94(10):e1027–e1039. https://doi.org/10.1212/WNL.0000000000008900CrossRefPubMedPubMedCentral

15.

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M, European Association for Neuro-Oncology Task Force on Primary CNSL (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European association for neuro-oncology. Lancet Oncol 16(7):e322-332. https://doi.org/10.1016/S1470-2045(15)00076-5CrossRefPubMed

16.

Armand M, Costopoulos M, Osman J, Tarfi S, Houillier C, Choquet S, Agnelo H, Bonnemye P, Ronez E, Settegrana C, Soussain C, Hoang-Xuan K, Le Garff-Tavernier M, Davi F (2019) Optimization of CSF biological investigations for CNS lymphoma diagnosis. Am J Hematol 94(10):1123–1131. https://doi.org/10.1002/ajh.25578CrossRefPubMed

17.

Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62(6):865–870. https://doi.org/10.1001/archneur.62.6.865CrossRefPubMed

18.

Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, Santiago-Raber ML, Hochstrasser DF, Lalive PH (2013) Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE 8(8):e72399. https://doi.org/10.1371/journal.pone.0072399CrossRefPubMedPubMedCentral

19.

Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40(11):1735–1739. https://doi.org/10.1212/wnl.40.11.1735CrossRefPubMed

20.

Chazal T, Costopoulos M, Maillart E, Fleury C, Psimaras D, Legendre P, Pineton de Chambrun M, Haroche J, Lubetzki C, Amoura Z, Legarff-Tavernier M, Cohen Aubart F (2019) The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study. Eur J Neurol 26(10):1274–1280. https://doi.org/10.1111/ene.13975CrossRefPubMed

21.

Banks WA, Kastin AJ, Gutierrez EG (1994) Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 179(1–2):53–56. https://doi.org/10.1016/0304-3940(94)90933-4CrossRefPubMed

22.

Banks WA (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm Des 11(8):973–984. https://doi.org/10.2174/1381612053381684CrossRefPubMed

Titel: CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma
verfasst von: Aurelian Ungureanu
Magali Le Garff-Tavernier
Myrto Costopoulos
Timothée Parratte
Abdelmalek Brinet
Hélène Durand
Claude Gaultier
Remy Hurstel
Isabelle Alamome
François Sellal
Guido Ahle
Publikationsdatum: 20.02.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 8/2021
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10453-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Discussion and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature

Contribution of neuropsychiatric symptoms in Parkinson’s disease to different domains of caregiver burden

Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up

Recurrent seizures of autoimmune origin: emerging phenotypes

Heterogeneity of behavioural and language deficits in FTD–MND

Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)